Company: MIRA
Filing Date: 2025-08-08
Form Type: DEFM14A
Source: 0001641172-25-022816
Chunk: 40

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-08
Form: DEFM14A
Chunk 40
---
 claims may result in:

| 18 |

| ● | decreased demand for SKNY product candidates if such product candidates 
 are approved;                                                           |
| ● | injury                                                                  
 to our reputation;                                                      |
| ● | withdrawal                                                              
 of clinical trial participants;                                         |
| ● | costs                                                                   
 of related litigation;                                                  |
| ● | substantial                                                             
 monetary awards to patients and others;                                 |
| ● | increased                                                               
 cost of liability insurance;                                            |
| ● | loss                                                                    
 of revenue; and                                                         |
| ● | the                                                                     
 inability to successfully commercialize our products.                   |

SKNY depends upon its key personnel and ability to attract and retain employees.

SKNY’s future growth and success depend on its ability to recruit, retain, manage, and motivate employees. The inability to hire or retain experienced management personnel could adversely affect SKNY’s ability to execute its business plan and harm its operating results. Due to the specialized scientific and managerial nature of SKNY’s business, it relies heavily on its ability to attract and retain qualified scientific, technical, and managerial personnel. The competition for qualified personnel in the pharmaceutical field is intense. Due to this intense competition, SKNY may be unable to attract and retain the qualified personnel necessary for the development of its business or to recruit suitable replacement personnel.

SKNY is subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing its operations. If SKNY fails to comply with these laws, it could be subject to civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect its business, results of operations and financial condition.

SKNY’s operations are subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”), and other anti-corruption laws that apply in countries where it does business. The FCPA and these other laws generally prohibit SKNY’s and its employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. SKNY is likely to operate in a number of jurisdictions that pose a high risk of potential FCPA violations, and SKNY participation in collaborations and relationships with third parties could potentially subject SKNY to liability under the FCPA or local anti-corruption laws. In addition, SKNY cannot predict the nature, scope, or effect